

Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

NCT06554288

| | |
|------------|---------------------------------------|
| Status | RECRUITING |
| Phase | Phase 1 |
| Sponsor | Children's Mercy Hospital Kansas City |
| Enrollment | 40 participants |

Key Eligibility Criteria

Inclusion (4)

- Ages 5-17 years of age
- Diagnosis of cerebral palsy and dystonia causing interference
- Parent/legal guardian of a child with a diagnosis of cerebral palsy and dystonia
- Parent/legal guardian is willing and able to provide informed permission/assent for the study

Exclusion (3)

- Previously or currently taking trihexyphenidyl
- Patients turning 18 years of age within the study period (16 weeks from Study Day 1)
- A language barrier for the patient that precludes communication and/or the ability to complete study-related requirements

Locations (1 total)

Children's Mercy Hospital Kansas City, Kansas City, Missouri, United States